Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer

التفاصيل البيبلوغرافية
العنوان:	Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
المؤلفون:	Jun NI, Miao HUANG, Li ZHANG, Nan WU, Chunxue BAI, Liang’an CHEN, Jun LIANG, Qian LIU, Jie WANG, Yilong WU, Fengchun ZHANG, Shuyang ZHANG, Chun CHEN, Jun CHEN, Wentao FANG, Shugeng GAO, Jian HU, Tao JIANG, Shanqing LI, Hecheng LI, Yongde LIAO, Yang LIU, Deruo LIU, Hongxu LIU, Jianyang LIU, Lunxu LIU, Mengzhao WANG, Changli WANG, Fan YANG, Yue YANG, Lanjun ZHANG, Xiuyi ZHI, Wenzhao ZHONG, Yuzhou GUAN, Xiaoxiao GUO, Chunxia HE, Shaolei LI, Yue LI, Naixin LIANG, Fangliang LU, Chao LV, Wei LV, Xiaoyan SI, Fengwei TAN, Hanping WANG, Jiangshan WANG, Shi YAN, Huaxia YANG, Huijuan ZHU, Junling ZHUANG, Minglei ZHUO
المصدر:	Chinese Journal of Lung Cancer, Vol 24, Iss 3, Pp 141-160 (2021)
بيانات النشر:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2021.
سنة النشر:	2021
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	lung neoplasms, perioperative immunotherapy, immune checkpoint inhibitor related adverse events, clinical recommendation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف:	Background and objective Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). Methods This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. Results This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. Conclusion Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	Chinese
تدمد:	1009-3419 1999-6187
Relation:	https://doaj.org/toc/1009-3419; https://doaj.org/toc/1999-6187
DOI:	10.3779/j.issn.1009-3419.2021.101.06
URL الوصول:	https://doaj.org/article/463505d96c91469a815ec257e1195391
رقم الانضمام:	edsdoj.463505d96c91469a815ec257e1195391
قاعدة البيانات:	Directory of Open Access Journals

View record in DOAJ

Full Text Finder

ResultId	1
Header	edsdoj Directory of Open Access Journals edsdoj.463505d96c91469a815ec257e1195391 949 3 Academic Journal academicJournal 948.697387695313
PLink	https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.463505d96c91469a815ec257e1195391&custid=s6537998&authtype=sso
FullText	Array ( [Availability] => 0 ) Array ( [0] => Array ( [Url] => https://doaj.org/article/463505d96c91469a815ec257e1195391 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=10093419&ISBN=&volume=24&issue=3&date=20210301&spage=141&pages=141-160&title=Chinese Journal of Lung Cancer&atitle=Clinical%20Recommendations%20for%20Perioperative%20Immunotherapy-induced%20Adverse%20Events%20in%20Patients%20with%20Non-small%20Cell%20Lung%20Cancer&id=DOI:10.3779/j.issn.1009-3419.2021.101.06 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items	Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer ) Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Jun+NI%22">Jun NI</searchLink><br /><searchLink fieldCode="AR" term="%22Miao+HUANG%22">Miao HUANG</searchLink><br /><searchLink fieldCode="AR" term="%22Li+ZHANG%22">Li ZHANG</searchLink><br /><searchLink fieldCode="AR" term="%22Nan+WU%22">Nan WU</searchLink><br /><searchLink fieldCode="AR" term="%22Chunxue+BAI%22">Chunxue BAI</searchLink><br /><searchLink fieldCode="AR" term="%22Liang%27an+CHEN%22">Liang’an CHEN</searchLink><br /><searchLink fieldCode="AR" term="%22Jun+LIANG%22">Jun LIANG</searchLink><br /><searchLink fieldCode="AR" term="%22Qian+LIU%22">Qian LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Jie+WANG%22">Jie WANG</searchLink><br /><searchLink fieldCode="AR" term="%22Yilong+WU%22">Yilong WU</searchLink><br /><searchLink fieldCode="AR" term="%22Fengchun+ZHANG%22">Fengchun ZHANG</searchLink><br /><searchLink fieldCode="AR" term="%22Shuyang+ZHANG%22">Shuyang ZHANG</searchLink><br /><searchLink fieldCode="AR" term="%22Chun+CHEN%22">Chun CHEN</searchLink><br /><searchLink fieldCode="AR" term="%22Jun+CHEN%22">Jun CHEN</searchLink><br /><searchLink fieldCode="AR" term="%22Wentao+FANG%22">Wentao FANG</searchLink><br /><searchLink fieldCode="AR" term="%22Shugeng+GAO%22">Shugeng GAO</searchLink><br /><searchLink fieldCode="AR" term="%22Jian+HU%22">Jian HU</searchLink><br /><searchLink fieldCode="AR" term="%22Tao+JIANG%22">Tao JIANG</searchLink><br /><searchLink fieldCode="AR" term="%22Shanqing+LI%22">Shanqing LI</searchLink><br /><searchLink fieldCode="AR" term="%22Hecheng+LI%22">Hecheng LI</searchLink><br /><searchLink fieldCode="AR" term="%22Yongde+LIAO%22">Yongde LIAO</searchLink><br /><searchLink fieldCode="AR" term="%22Yang+LIU%22">Yang LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Deruo+LIU%22">Deruo LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Hongxu+LIU%22">Hongxu LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Jianyang+LIU%22">Jianyang LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Lunxu+LIU%22">Lunxu LIU</searchLink><br /><searchLink fieldCode="AR" term="%22Mengzhao+WANG%22">Mengzhao WANG</searchLink><br /><searchLink fieldCode="AR" term="%22Changli+WANG%22">Changli WANG</searchLink><br /><searchLink fieldCode="AR" term="%22Fan+YANG%22">Fan YANG</searchLink><br /><searchLink fieldCode="AR" term="%22Yue+YANG%22">Yue YANG</searchLink><br /><searchLink fieldCode="AR" term="%22Lanjun+ZHANG%22">Lanjun ZHANG</searchLink><br /><searchLink fieldCode="AR" term="%22Xiuyi+ZHI%22">Xiuyi ZHI</searchLink><br /><searchLink fieldCode="AR" term="%22Wenzhao+ZHONG%22">Wenzhao ZHONG</searchLink><br /><searchLink fieldCode="AR" term="%22Yuzhou+GUAN%22">Yuzhou GUAN</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoxiao+GUO%22">Xiaoxiao GUO</searchLink><br /><searchLink fieldCode="AR" term="%22Chunxia+HE%22">Chunxia HE</searchLink><br /><searchLink fieldCode="AR" term="%22Shaolei+LI%22">Shaolei LI</searchLink><br /><searchLink fieldCode="AR" term="%22Yue+LI%22">Yue LI</searchLink><br /><searchLink fieldCode="AR" term="%22Naixin+LIANG%22">Naixin LIANG</searchLink><br /><searchLink fieldCode="AR" term="%22Fangliang+LU%22">Fangliang LU</searchLink><br /><searchLink fieldCode="AR" term="%22Chao+LV%22">Chao LV</searchLink><br /><searchLink fieldCode="AR" term="%22Wei+LV%22">Wei LV</searchLink><br /><searchLink fieldCode="AR" term="%22Xiaoyan+SI%22">Xiaoyan SI</searchLink><br /><searchLink fieldCode="AR" term="%22Fengwei+TAN%22">Fengwei TAN</searchLink><br /><searchLink fieldCode="AR" term="%22Hanping+WANG%22">Hanping WANG</searchLink><br /><searchLink fieldCode="AR" term="%22Jiangshan+WANG%22">Jiangshan WANG</searchLink><br /><searchLink fieldCode="AR" term="%22Shi+YAN%22">Shi YAN</searchLink><br /><searchLink fieldCode="AR" term="%22Huaxia+YANG%22">Huaxia YANG</searchLink><br /><searchLink fieldCode="AR" term="%22Huijuan+ZHU%22">Huijuan ZHU</searchLink><br /><searchLink fieldCode="AR" term="%22Junling+ZHUANG%22">Junling ZHUANG</searchLink><br /><searchLink fieldCode="AR" term="%22Minglei+ZHUO%22">Minglei ZHUO</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Chinese Journal of Lung Cancer, Vol 24, Iss 3, Pp 141-160 (2021) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2021. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22lung+neoplasms%22">lung neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22perioperative+immunotherapy%22">perioperative immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22immune+checkpoint+inhibitor+related+adverse+events%22">immune checkpoint inhibitor related adverse events</searchLink><br /><searchLink fieldCode="DE" term="%22clinical+recommendation%22">clinical recommendation</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background and objective Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). Methods This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. Results This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. Conclusion Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => Chinese ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1009-3419<br />1999-6187 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/1009-3419; https://doaj.org/toc/1999-6187 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3779/j.issn.1009-3419.2021.101.06 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/463505d96c91469a815ec257e1195391" linkWindow="_blank">https://doaj.org/article/463505d96c91469a815ec257e1195391</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.463505d96c91469a815ec257e1195391 )
RecordInfo	Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.3779/j.issn.1009-3419.2021.101.06 ) ) [Languages] => Array ( [0] => Array ( [Text] => Chinese ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 20 [StartPage] => 141 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => lung neoplasms [Type] => general ) [1] => Array ( [SubjectFull] => perioperative immunotherapy [Type] => general ) [2] => Array ( [SubjectFull] => immune checkpoint inhibitor related adverse events [Type] => general ) [3] => Array ( [SubjectFull] => clinical recommendation [Type] => general ) [4] => Array ( [SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [5] => Array ( [SubjectFull] => RC254-282 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jun NI ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Miao HUANG ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Li ZHANG ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nan WU ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chunxue BAI ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Liang’an CHEN ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jun LIANG ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Qian LIU ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jie WANG ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yilong WU ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fengchun ZHANG ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shuyang ZHANG ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chun CHEN ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jun CHEN ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wentao FANG ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shugeng GAO ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jian HU ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tao JIANG ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shanqing LI ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hecheng LI ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yongde LIAO ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yang LIU ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Deruo LIU ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hongxu LIU ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jianyang LIU ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lunxu LIU ) ) ) [26] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mengzhao WANG ) ) ) [27] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Changli WANG ) ) ) [28] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fan YANG ) ) ) [29] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yue YANG ) ) ) [30] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lanjun ZHANG ) ) ) [31] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiuyi ZHI ) ) ) [32] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wenzhao ZHONG ) ) ) [33] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yuzhou GUAN ) ) ) [34] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoxiao GUO ) ) ) [35] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chunxia HE ) ) ) [36] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shaolei LI ) ) ) [37] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Yue LI ) ) ) [38] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Naixin LIANG ) ) ) [39] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fangliang LU ) ) ) [40] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chao LV ) ) ) [41] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wei LV ) ) ) [42] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xiaoyan SI ) ) ) [43] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fengwei TAN ) ) ) [44] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hanping WANG ) ) ) [45] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jiangshan WANG ) ) ) [46] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shi YAN ) ) ) [47] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Huaxia YANG ) ) ) [48] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Huijuan ZHU ) ) ) [49] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Junling ZHUANG ) ) ) [50] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Minglei ZHUO ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 03 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 10093419 ) [1] => Array ( [Type] => issn-print [Value] => 19996187 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 24 ) [1] => Array ( [Type] => issue [Value] => 3 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Chinese Journal of Lung Cancer [Type] => main ) ) ) ) ) ) )
IllustrationInfo